Related posts:
- BRIEF-Genentech says phase III study evaluating Gazyva did not meet primary endpoint
- Heard the one about ‘The Skyscraper Curse’ & market crashes? Yeah, its rubbish.
- BRIEF-Nutanix sees IPO price of class A common stock between $11-$13/shr – SEC filing
- Airbus net orders fall as it draws line under Kingfisher failure